- Rafick-Pierre Sékaly
Affiliation : Université de Montréal
Organization : CHUM - Hôpital Saint Luc
E-mail : email@example.com
About Rafick-Pierre Sékaly
Rafick-Pierre Sékaly, a full professor at Université de Montréal, is the Scientific Director of the National Immune-Monitoring Laboratory (NIML, University of Montreal) and the Unit 743 of Inserm (Institut national de la Santé et de la recherche médicale). Dr. Sékaly is also Associate Scientific Director (Basic Sciences and Strategy) at CHUM. He received several honours and awards including the Cinader Award from the Canadian Society for Immunology (2007). He became a member of the Canadian Academy of Health Sciences in 2006 and obtained the Canadian research Chair in Immunology (CIHR) in 2001. He has also received a Doctoral Fellowship of the Ludwig Institute for Cancer Research of Switzerland, the Forgaty Fellowship of the National Institutes of Health of Maryland and the fellowships named Chercheur-boursier «Senior 1» of the Fonds de la recherche en santé du Québec, Prix du jeune chercheur of the Club de recherches cliniques du Québec and Senior Scientist Salary Support Awards from the Medical Research Council of Canada. Dr Sékaly obtained his Ph.D. in Biochemistry at the Université de Lausanne in 1984 and then performed a postdoctoral fellowship, from 1984 to 1987, on immunogenetics and molecular biology of major histocompatibility complex molecules. Dr. Rafick-Pierre Sékaly has been involved in the areas of HIV and AIDS for the past fifteen years. Dr. Rafick-Pierre Sékaly has made outstanding contributions to investigations of mechanisms of T cell activation and death, HIV pathogenesis, particularly in the area of primary infection. He has also been at the forefront of clinical trials investigating therapeutic vaccines and immune reconstitution. His work has been published in outstanding journals such as Nature, Nature Medicine and the Journal of Experimental Medicine. As Founder and Scientific Director of the NIML, Dr. Sékaly hopes to improve the quality of life of Canadians by using novel technologies and a multidisciplinary approach in order to develop vaccines for the prevention and treatment of chronic diseases like HIV, hepatitis C and cancer.